ライフサイエンスコーパス: systemic reaction

1 ch a diagnosis and may predict the risk of a systemic reaction.

2 of the 21 subjects who received stings had a systemic reaction.

3 anut-allergic subjects suffering from severe systemic reactions.

4 There were no serious local or systemic reactions.

5 reported a higher incidence of food-induced systemic reactions.

6 ated with mostly mild and transient local or systemic reactions.

7 rointestinal AEs, and AR predicted increased systemic reactions.

8 Ultrarush initiation increases the risk of systemic reactions.

9 dministration intervals, but it caused fewer systemic reactions.

10 es include nuisance biting and cutaneous and systemic reactions.

11 een reported, including cutaneous and rarely systemic reactions.

12 that are associated with a high incidence of systemic reactions.

13 stration is associated with a risk of severe systemic reactions.

14 atients (8.3% of all patients) experienced 6 systemic reactions (0.15% of doses).

15 Anaphylactic shock (76.6%), severe systemic reactions (10.5%), acute laryngeal edema (9%),

16 form of meat allergy characterized by severe systemic reactions 3-7 h after consumption of red meat.

17 ll tolerated, with occasional, usually mild, systemic reactions (abdominal pain, arthralgia, and diar

18 However, rates of local induration, systemic reactions, adverse events (AEs), and SAEs were

19 Local and systemic reactions after vaccination with LC16m8 were si

20 blet (SLIT-tablet) treatment, such as severe systemic reactions and asthma-related events.

21 However, systemic reactions and intolerable gastrointestinal AEs

22 ll-tolerated with only grade 1 to 2 local or systemic reactions and no treatment-limiting adverse eve

23 Approximately 42% of subjects experienced systemic reactions, and 49% experienced gastrointestinal

24 se showed promising efficacy, small risk for systemic reactions, and immunomodulatory changes in this

25 avenous immunoglobulin (IGIV), induces fewer systemic reactions, and may be self-infused.

26 Vaccine administration induced no local or systemic reactions, and no laboratory abnormalities were

27 A 51-year-old woman experienced systemic reactions beginning 10 days after cadaveric ren

28 with no significant differences in local or systemic reactions between groups.

29 se 4 was associated with increased local and systemic reactions, but the overall safety profile of a

30 all patients suggesting a radiation-induced systemic reaction; (c) changes in DTPA t 1/2 values were

31 (pain, erythema, induration, and warmth) and systemic reactions (chills, arthralgias, and myalgias) i

32 me was the occurrence of 1 or more objective systemic reactions during venom immunotherapy initiation

33 Treatment options for cutaneous and systemic reactions from bed bug bites have not been eval

34 p large local swelling or strictly cutaneous systemic reactions generally do not require immunotherap

35 frequently reported adverse events included systemic reactions (Group 1: 21% of patients, Group 2: 3

36 ed and who had a history of mild (cutaneous) systemic reaction (i.e., one with only cutaneous manifes

37 We sought to investigate the occurrence of systemic reactions in children with isolated sensitizati

38 er incidence of mild, self-limited local and systemic reactions in the vaccine group, but only during

39 well tolerated, with no significant local or systemic reactions in the women and no adverse outcomes

40 om immunotherapy may reduce the incidence of systemic reactions in those with a history of venom-trig

41 Systemic reactions included mild to moderate malaise and

42 nd in untreated patients with a history of a systemic reaction involving at least two different organ

43 as associated with mild-to-moderate local or systemic reactions lasting a median of three days.

44 Local, mild, or severe systemic reactions may occur already after the first con

45 s (aP) vaccines has considerably reduced the systemic reactions observed with diphtheria-tetanus toxo

46 Systemic reactions occurred less frequently in patients

47 Local or systemic reactions occurred, respectively, in 40 (78%) a

48 No systemic reactions occurred.

49 The acute-phase response (APR) represents a systemic reaction of the organism to multiple nonspecifi

50 eater number of moderate or severe local and systemic reactions (of 16 participants, 4 had local reac

51 There was no pattern of vaccine-associated systemic reactions or clinically significant laboratory

52 1.0 kUA /l conferred a 97% probability for a systemic reaction (P = 0.0002).

53 sociated with a higher frequency of local or systemic reactions (P = 0.001, both).

54 ensitization and region on the occurrence of systemic reactions (P = 0.0185 and P = 0.0436, respectiv

55 nts of the higher dose had greater local and systemic reactions (P<.001).

56 , 7 had local reactions [P < 0.01] and 0 had systemic reactions [P < 0.001]).

57 ntrast administration can be associated with systemic reactions, renal disease, and thyroid dysfuncti

58 he association between sBT levels and severe systemic reactions (SR).

59 Outside clinical trials, data on systemic reactions (SRs) due to allergen immunotherapy (

60 fact stimulate more robust inflammatory and systemic reactions than RF at liver ablation, the author

61 rticipants, 4 had local reactions and 13 had systemic reactions) than did vaccine formulated with MF5

62 errulatus-envenomed victims exhibit local or systemic reaction that culminates in pulmonary oedema, p

63 Trauma evokes a systemic reaction that includes an acute, non-specific,

64 Four subjects had adverse systemic reactions that may have resulted from the inten

65 against GVHD, vaccination elicited local and systemic reactions that were qualitatively similar to th

66 There is evidence that the severity of the systemic reaction to infection (severe sepsis) is strong

67 d food challenge, 1 boy with a previous mild systemic reaction to peanut experienced lip swelling, st

68 ldren leads to a significantly lower risk of systemic reaction to stings even 10 to 20 years after tr

69 espiratory symptoms but inversely related to systemic reactions to food.

70 sp venom, and 32 controls without history of systemic reactions to Hymenoptera stings and no sIgE to

71 re considered to be a risk factor for severe systemic reactions to hymenoptera stings.

72 known to occur in a subset of patients with systemic reactions to Hymenoptera stings.

73 tosis and/or elevated sBT tryptase level and systemic reactions to hymenoptera venoms were analyzed f

74 ificantly associated with the development of systemic reactions to peanut.

75 No severe or systemic reactions to vaccination occurred, and five ser

76 If the child had a documented history of systemic reactions up to grade I anaphylaxis, double-bli

77 plasma tryptase and EDN, and the severity of systemic reactions was correlated with levels of tryptas

78 Systemic reactions were counted to evaluate safety.

79 ccine immunogenicity, and rates of local and systemic reactions were determined.

80 Local and systemic reactions were generally mild and, except for p

81 The most common systemic reactions were headache, malaise, and myalgia.

82 Systemic reactions were less frequent with IGHy than wit

83 hough the overall reaction rate was similar, systemic reactions were more common during OIT than duri

84 Local and systemic reactions were more frequent after dose 4.

85 Objective systemic reactions were more likely during ultrarush ini

86 Although no acute cutaneous or systemic reactions were noted, endothelial cell activati

87 Mild local and systemic reactions were noted.

88 Systemic reactions were rare, but local reactions (prima

89 Immunotherapy was well tolerated; no systemic reactions were reported.

90 Stage 3 is the massive systemic reaction where cytokines turn destructive by co

91 frequency and severity of injection-site and systemic reactions within 28 days of each vaccination.

92 The primary safety endpoints were local and systemic reactions within 7 days after each injection, a

93 Solicited reports of injection-site and systemic reactions within 7 days after vaccination were

94 , at 4-7 days for postimmunization local and systemic reactions, within 28 days for adverse events, a